Skip to main content

Research News

 

Clinical courses

  • Loss of Auditory Nerve Fibers Uncovered in Individuals with Tinnitus

    A new study from Mass Eye and Ear investigators shows that individuals who report tinnitus, which present as a ringing in the ears in more than one out of ten adults worldwide, are experiencing auditory nerve loss that is not picked up by conventional hearing tests.

  • A patch of protection against Zika virus

    A simple-to-apply, needle-free vaccine patch is being developed to protect people from the potentially deadly mosquito-borne Zika virus.

    A prototype using The University of Queensland-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP) has delivered a University of Adelaide-developed vaccine and elicited an effective immune response to Zika virus in mice.

  • Nano-sized cell particles are promising intervention tool in treating infectious diseases

    The COVID-19 pandemic demonstrated the importance of being prepared with drug interventions to contain viral outbreaks that can otherwise have devastating consequences. In preparing for the next pandemic—or Disease X, there is an urgent need for versatile platform technologies that could be repurposed upon short notice, to combat infectious outbreaks.

  • Novel study finds aspirin-free regimen benefits patients with LVAD

    The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of a fully magnetically levitated left ventricular assist device (LVAD).

  • Researchers Develop a New Model by Leveraging an Old Vaccine to Build Better Tuberculosis Vaccines

    Despite TB’s wide reach and some lost progress during the COVID-19 pandemic, researchers believe it is possible to eradicate TB through advances in vaccine development and public health. To cross the finish line, scientists must find ways to test new vaccines rapidly to prevent TB infections more effectively. 

  • Researchers Identify Cell Signaling Pathway Controlling Melanoma Cell Metastasis to the Brain

    Melanoma is the deadliest form of skin cancer because of its ability to quickly grow and spread throughout the body. More than half of those with advanced melanoma will see the disease spread to the brain, where it rapidly progresses, often leading to death in only three to four months. Researchers in Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have been working to better understand what drives melanoma brain metastasis.

  • Repairing nerve cells after injury and in chronic disease

    Each year in the United States there are more than 3 million cases of peripheral neuropathy, wherein nerves outside of the brain and spinal cord are damaged and cause pain and loss of feeling in the affected areas. Peripheral neuropathy can occur from diabetes, injury, genetically inherited disease, infection, and more. Salk scientists have now uncovered in mice a mechanism for repairing damaged nerves during peripheral neuropathy. They discovered that the protein Mitf helps turn on the repair function of specialized nervous system Schwann cells. 

  • Neurodegeneration in Myelin Disease : No Myelin is Better than Bad Myelin

    Myelin is an insulating sheath around axons - the processes connecting nerve cells - that is mostly composed of lipids and proteins. It enables rapid conduction of electrical signals and supports neuronal integrity and function. In the central nervous system, myelin is formed by specialized glial cells called oligodendrocytes. Myelinated fiber tracts are particularly vulnerable to various pathogenic processes and myelin diseases are often associated with chronic inflammation of the nervous system.

  • Stem cell-based treatment controls blood sugar in people with Type 1 diabetes

    An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results from the University of British Columbia (UBC) and Vancouver Coastal Health (VCH).

  • New platform solves key problems in targeted drug delivery

    In recent years, cell and gene therapies have shown significant promise for treating cancer, cystic fibrosis, diabetes, heart disease, HIV/AIDS and other difficult-to-treat diseases. But the lack of effective ways to deliver biological treatments into the body has posed a major barrier for bringing these new therapies to the market — and, ultimately, to the patients who need them most.

Subscribe to Research News